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The insulin-like growth factor receptor I (IGF-IR) is a proto-oncogene with potent mitogenic and
antiapoptotic activities. It has been reported that expression of IGF-IR is up-regulated in bladder
cancer. Here, we assessed whether microRNA-145 (miR-145) regulates IGF-IR expression in bladder
cancer. In our study, miR-145 was shown to directly target IGF-IR 30-untranslated region (UTR) in
human bladder cancer cells. Small interfering RNA (siRNA)- and miR-145-mediated IGF-IR knock-
down experiments revealed that miR-145 promotes cell apoptosis, and suppresses cell proliferation
and migration through suppression of IGF-IR expression. Taken together, our data suggest that
miR-145 may inhibit bladder cancer initiation by affecting IGF-IR signaling.
 2014 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Bladder cancer is the second most common urological malig-
nancy in the United States of America and is by far the most fre-
quent urological malignancy in China. Based on incidence and
mortality data from several agencies, the American Cancer Society
estimates that 72570 new bladder cancer cases and 15210 deaths
from bladder cancer are projected to occur in the United States in
2013 [1]. Noteworthy, more than 90% of bladder cancers are tran-
sitional cell carcinomas. Despite signiﬁcant advances in surgical
techniques and adjuvant chemotherapy, bladder cancer remains
a highly prevalent and lethal malignancy [2]. Therefore, novel
treatment strategies based on new molecular networks are
urgently needed to improve the poor prognosis in patients with
bladder cancer.
MicroRNAs (miRNAs) are small non-coding RNAs which regu-
late a plethora of biological processes including cell proliferation,
cell differentiation and apoptosis [3]. Through interactions withthe 30-untranslated region (30-UTR) of mRNA by partial sequence
homology, miRNAs regulate gene expression either by mRNA deg-
radation or translation repression. Increasing evidence indicates
that miRNAs are aberrantly expressed in many human cancers,
and they may function as either oncogenes or tumor suppressors
[4]. The miR-145 has been commonly identiﬁed as a tumor
suppressive miRNA which is down-regulated in various human
malignancies: colon cancer [5], lung cancer [6], prostate cancer
[7], breast cancer [8,9], and bladder cancer [10,11].
The insulin-like growth factor receptor I (IGF-IR) is a cellular
receptor found to be upregulated in tumors from different anatom-
ical sites. A growing body of evidence indicates that the IGF-IR
plays a critical role in transformation by promoting cell growth
and protecting cancer cells from apoptosis [12]. It has been sug-
gested that IGF-IR is overexpressed in bladder cancer compared
with non-malignant bladder [12,13]. Moreover, activation of the
IGF-IR could promote motility and invasion of bladder cancer cells.
However, it is not known whether IGF-IR expression is regulated
by speciﬁc miRNAs in bladder cancer.
Shi and colleagues demonstrated that IGF-IR protein levels were
down-regulated by the transfection of synthetic miR-145 oligonu-
cleotides [14]. Moreover, the 30UTR of the IGF-IR is required for
down-regulation by miR-145 [15]. Based on these results, we
hypothesised that IGF-IR knockdown via miR-145 may be a new
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we used a luciferase reporter assay to determine whether miR-
145 binds to the 30UTR of IGF-IR mRNA and affect the function
(proliferation, apoptosis and migration) of bladder cancer cells.
Finally, we knocked down IGF-IR mRNA using a small interfering
RNA (siRNA) technique to examine the mechanism of miR-145
tumor-suppressive function, thereby increasing the understanding
for its reduction in bladder cancer.
2. Material and methods
2.1. Cell culture
Human urinary bladder transitional cell carcinoma (T24, 5637)
and immortalized human bladder epithelium (TCHu169) cells
were obtained from Chinese Academy of Science (Shanghai, China).
The T24 and 5637 cell line were maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS). The TCHu169
cells were propagated in F-12K medium containing 10% FBS. All
media contained 100 units of penicillin/mL and 100 lg of strepto-
mycin/mL. Cells were incubated in a humidiﬁed atmosphere of 5%
CO2 and 95% air at 37 C. Bladder cancer cells were treated with
recombinant human IGF-I (R&D Systems, Inc., MN, USA) in starva-
tion medium. Based on preliminary dose–response experiments,
50 ng/mL IGF-I was selected for use in all experiments in the pres-
ent study.
2.2. miRNAs, small interfering RNAs and transfection
miR-145 mimic and the negative control were synthesized by
RiboBio (Guangzhou, China). For convenience, miR-145 mimic
and the negative control are termed miR-145 and miR-NC, respec-
tively. Small interfering RNAs (siRNAs) against IGF-IR were also
obtained from RiboBio (Guangzhou, China). miR-145 and miR-NC
were used in the gain-of-function experiments, whereas IGF-IR
siRNA and negative-control siRNA were used in the loss-of-func-
tion experiments. miRNAs and siRNAs transfection was performed
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instruction. Cells were seeded in a
10-cm dish for RNA and protein extraction, in a six-well plate for
apoptosis and wound healing assay, and in a 96-well plate for
MTT assay and luciferase reporter assay.
2.3. Cell proliferation assay
Cell growth was determined using an MTT assay performed
according to the manufacturer’s instructions. Cells were plated in
96-well plates in triplicate and cultured in the growth medium.
The number of cells per well were measured by the absorbance
(540 nm) of (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazoli-
um Bromide) (Invitrogen, Carlsbad, CA, USA) at the indicated time
points.
2.4. Apoptosis analysis
Cells were harvested 48 h after transfection by trypsinisation
and washed in cold phosphate-buffered saline (PBS). Double stain-
ing with Alexa Fluor 488 annexin V and propidium iodide (PI) was
carried out using Alexa Fluor 488 annexin V/Dead Cell Apoptosis
Kit (Invitrogen, USA) according to the manufacturer’s recommen-
dations and immediately analyzed within an hour by ﬂow cytom-
etry (FACScan, BD Biosciences). Cells were discriminated into
viable cells, dead cells, early apoptotic cells, and apoptotic cells,
and then the apoptotic distribution of the cells in each sample
was determined using the CellQuest Software (BD Biosciences,
USA).2.5. Wound healing assay
Cell migration activity was evaluated by wound healing assay as
described previously [16,17]. Cells were plated in six-well dishes,
and the cell monolayer was scraped using a micropipette tip. The
initial gap length (0 h) and the residual gap length 24 h after
wounding were calculated from Photomicrographs.
2.6. Luciferase assay
The 30UTR of human IGF-IR cDNA containing the putative target
site for the mature miR-145 was chemically synthesized and
inserted between the XhoI–NotI restriction sites, immediately
downstream of the luciferase gene in the pmiR-RB-REPORT™
vector by RiboBio Biotechnologies (Guangzhou, China). The cells
were plated in 96-well plates and transfected with 35 ng of
IGF-IR-30UTR-WT or IGF-IR-30UTR-Mut, and 50 nM of the mature
miR-145 mimic or the negative control, using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s protocol as described. Then, the cells were harvested and
lysed for luciferase assay 48 h after transfection. The activities of
ﬁreﬂy and Renilla luciferases in cell lysates were determined using
the Dual Luciferase Reporter Assay System (Promega, Madison, WI,
USA). Normalised data were calculated as the quotient of Renilla/
ﬁreﬂy luciferase activities. Three independent experiments were
performed in triplicate.
2.7. RNA isolation, reverse transcription, and quantitative real-time
PCR
Total RNA was extracted from the human bladder cancer cell
line (T24, 5637) and the human normal urothelial cells (TCHu169),
using Trizol reagent (Invitrogen, USA) according to the manufac-
turer’s protocol. For miR-145 and U6 snRNA, cDNA was synthe-
sized with Bulge-loop primers and the primeScript miRNA cDNA
Synthesis Kit (TaKaRa Biotechnology, Dalian, China). The U6 small
nuclear B non-coding RNA (RNU6B) level was used as an internal
normalization control. Real-time PCR was done by using the SYBR
Premix Ex Taq (TaKaRa). For IGF-IR, cDNA was synthesized using
the PrimeScript RT-PCR Kit (TaKaRa) and Quantitative RT-PCR
was performed using the SYBR Premix Ex Taq (TaKaRa). b-Actin
was used to normalize the IGF-IR-mRNA expression level. All quan-
titative RT-PCR was performed in triplicate on an Applied Biosys-
tems 7500 Real-time PCR system (Applied Biosystems, Carlsbad,
CA, USA). All the primers were synthesized from RiboBio biotech-
nology (Guangzhou, China). The comparative threshold cycle
method was used to calculate the relative gene expression.
2.8. Protein extraction and Western blot
Bladder cancer cells were seeded onto six-well plates the day
before transfections were performed. Forty-eight hours after trans-
fection, cells were lysed with RIPA buffer containing protease
inhibitors (Beyotime biotechnology, Haimen, China). The concen-
trations of the proteins were determined using a BCA Protein Assay
Kit (Beyotime biotechnology, Haimen, China). Samples were
thawed in 5  SDS–PAGE sample loading buffer, vortexed and then
denatured at 100 C for 5 min and placed on ice for 5 min. Cell
lysates (approximately 30 lg of protein) were loaded on an 8%
SDS–PAGE gel and subsequently transferred to a polyvinylidene
diﬂuoride (PVDF) membrane (Millipore, Billerica, MA, USA) by
Wet Electrophoretic Transfer (Bio-Rad Laboratories). The mem-
branes were blocked for 1 h at room temperature, and incubated
overnight at 4 C with Rabbit anti-IGF-IR antibody (Abcam,
Cambridge, MA, USA) diluted 1:500 or anti-b-Actin monoclonal
antibody diluted 1: 2000 in Tris buffered saline with 0.05% tween
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the membranes were incubated with anti-rabbit horseradish per-
oxidase conjugated IgG (diluted 1:5000) as secondary antibody
and then visualized using commercial ECL kit (Millipore, Billerica,
MA, USA) according to the manufacturer’s protocol. The protein
bands were quantiﬁed using ImageJ 1.33 software (NIH), and the
data were normalized to b-actin.
2.9. Statistical analysis
All statistical analyses were performed using SPSS 15.0 for Win-
dows (SPSS Inc., Chicago, IL, USA). A P-value of less than 0.05 was
considered to be statistically signiﬁcant.
3. Results
3.1. Detection of miR-45 expression by quantitative stem-loop RT-PCR
The expression level of miR-145 was signiﬁcantly lower in
human bladder cancer T24 and 5637 cells in comparison with
normal bladder epithelial cells (TCHu169) (Fig. 1A and Fig. S1A).
The results in bladder cancer cells were consistent with those in
clinical bladder samples. At 48 h after transfection of miR-NC or
miR-145 into bladder cancer cells, the miR-145 expression level
was veriﬁed by quantitative stem-loop RT-PCR (Fig. 1B and
Fig. S1B).Fig. 1. miR-145 was down-regulated in bladder cancer T24 cells. (A) Expression of miR-
detected by qRT-PCR. (B) T24 cells were transfected with miR-145 mimic (50 nM). Expre
miR-145 was normalized with U6. Data were obtained in three independent experimen
Fig. 2. Effect of miR-145 overexpression on bladder cancer cell functions (T24). (A) Ce
cytometry analysis of apoptosis in miR-NC-transfected or miR-145-transfected T24 cells
Data represented three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with th3.2. Effects of miR-145 on cell proliferation, apoptosis and migration in
bladder cancer cells
We performed gain-of-function studies using transient miRNA-
145 transfectants of bladder cancer cells to investigate the
functional role of miR-145. The MTT assay revealed signiﬁcant cell
proliferation inhibition in miR-145 transfectant compared with the
control from T24 and 5637 cell line. Although IGF-I increased cell
proliferation in both T24 and 5637 cells, miR-145 could signiﬁ-
cantly abrogate the IGF1-induced cell viability in these cells
(Fig. 2A and Fig. S2). Apoptosis analysis based on ﬂowcytometry
was also performed with transfected bladder cancer cells (T24).
We observed a signiﬁcant increase in the number of apoptotic cells
in miR-145-transfected cells compared with the control (Fig. 2B).
The wound healing assay also showed signiﬁcant cell migration
inhibition in miR-145 transfectant (Fig. 2C).
3.3. 30-UTR luciferase assay and IGF-IR silencing by miR-145
transfection
As indicated by the TargetScan algorithm, IGF-IR mRNA has one
potential complimentary binding site with miR-145 within its
3’UTR (Fig. 3A). Based on this ﬁnding, we performed a luciferase
reporter assay to determine whether IGF-IR mRNA is target onco-
gene of miR-145. As shown in Fig. 3B, the luminescence intensity
was signiﬁcantly reduced in the miR-45 transfectant compared145 in human bladder cancer T24 cells and bladder epithelial cells (TCHu169) was
ssion of miR-145 was detected by qRT-PCR at 48 h after transfection. Expression of
ts. ⁄⁄P < 0.01 compared with the control.
ll viability assay (miR-NC-transfected or miR-145-transfected T24 cells). (B) Flow
. (C) Wound healing assay (miR-NC-transfected or miR-145-transfected T24 cells).
e control.
Fig. 3. IGF-IR was a direct target of miR-145. (A) The potential miR-145 binding sites of IGF-IR-30UTR and the mutated sequences. (B) T24 cells were co-transfected with miR-
145 or miR-NC with WT or MUT IGF-IR-30UTR. Luciferase activity was detected. (C) Expression of IGF-IR Protein was detected by Western blot in T24 cells transfected with
miR-145 or miR-NC. b-Actin was used as an internal control. (D) IGF-IR mRNA level was detected by qRT-PCR in cells transfected with miR-145 or miR-NC. ⁄⁄P < 0.01
compared with the control.
Fig. 4. IGF-IR expression in T24 cells after transfection with si-IGF-IR or si-Control. (A) IGF-IR mRNA expression was repressed in si-IGF-IR transfectants. (B) Western blot
analysis showed reduction in IGF-IR protein. ⁄⁄P < 0.01 compared with the control.
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IGF-IR-UTR-WT, and this suppression was abolished in the con-
struct with a mutant site (IGF-IR-UTR-Mut; Fig. 3B).
Next, we determined whether ectopic expression of miR-145
can suppress the endogenous IGF-IR at the protein level by
Western blot. The IGF-IR protein expression was signiﬁcantly
decreased in miR-145-transfected cells (Fig. 3C and Fig. S3A).
Real-time RT-PCR analysis detected a slight reduction of IGF-IR
mRNA in miR-145 cells compared with the control (Fig. 3D and
B), but this difference was not signiﬁcant, suggesting that miR-
145 silences IGF-IR mainly at the translational level.
3.4. Effect of IGF-IR knockdown on cell proliferation, apoptosis and
migration in bladder cancer cells (T24)
To look at whether miR-145 could exert its tumor-suppressive
function through IGF-IR, we knocked down IGF-IR mRNA using dif-
ferent si-IGF-IR transfections into T24 cell line. The knockdowneffect was conﬁrmed by measuring IGF-IR mRNA and protein
expression levels. As shown in Fig. 4A, the relative IGF-IR mRNA
expression level was signiﬁcantly decreased in siRNA-transfected
cells. Moreover, the protein expression of IGF-IR was also markedly
repressed by these si-IGF-IR transfections (Fig. 4B).
The MTT assay showed signiﬁcant cell-growth inhibition in the
two si-IGF-IR transfectants compared with si-control transfected
cells (Fig. 5A). As shown in Fig. 5B, the apoptotic cell fractions were
greater in the two si-IGF-IR transfectants than those in the si-con-
trol transfectant at 48 h after transfection. The wound healing
assay demonstrated signiﬁcant cell migration inhibitions in the
two si-IGF-IR transfectants compared with the counterparts
(Fig. 5C).
4. Discussion
Increasing evidence has suggested that dysregulation of certain
miRNAs may contribute to tumorigenesis. The implication of
Fig. 5. IGF-IR-knockdown effects on bladder cancer cell functions (T24). (A) Cell viability assay (si-Control-transfected or si-IGF-IR-transfected T24 cells). (B) Flow cytometry
analysis of apoptosis in si-Control-transfected or si-IGF-IR-transfected T24 cells s. (C) Wound healing assay (si-Control-transfected or si-IGF-IR-transfected T24 cells). Data
represented three independent experiments. ⁄P < 0.05, ⁄⁄P < 0.01 compared with the control.
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common deletion in human chronic lymphocyte leukemia (CLL)
harbors the miRNA genes encoding miR-15 and miR-16, the loss
of which is seen in 65% of all cases of CLL [18]. miRNAs have
emerged as central regulators of development, differentiation,
and cancer. Knowledge about the functional roles of speciﬁc miR-
NAs is steadily increasing; however, knowledge is still missing
for a large part of the identiﬁed miRNAs in this work. It has been
demonstrated that there are aberrant expression of miRNAs in
many human cancers, including bladder cancers [10,11,19], but
their important function and mechanisms in tumorigenesis are
far from being illustrated.
Approximately 50% of the miR genes are frequently located in
cancer-associated genomic regions or in fragile sites [20], which
may in part explain the low-level expression of miRNAs in cancer
samples. miR-145 is located at chromosome 5q32 in a putative
bicistronic cluster with miR-143 [21], a region commonly lost in
myelodysplastic syndromes [22]. Previous studies showed that
miR-145 was commonly down-regulated in several human cancers
and that their transfection could suppress cancer cell tumorigenic-
ity [23,6,24–26]. Thus, downregulation of miR-145 might have a
critical function in bladder cancer development.
Chiyomaru and colleagues performed gain-of-function studies
using Pre-miR and negative-control microRNA, and demonstrated
signiﬁcant cell-growth inhibition in miR-145 transfectant from
bladder cancer cells. Consistent with earlier studies [19,17], we
also observed signiﬁcant cell-growth inhibitions in human bladder
cancer T24 and 5637 cell line transfected with miR-145 mimic. To
directly demonstrate that the inhibitory action of miR-145 in blad-
der cancer cells happens through the inhibition of the IGF-IR path-
way, we treated cells with IGF-I and found that miR-145
expression could also affect IGF-I-induced cell viability. Ostenfeld
et al. found that miR-145 induces caspase-dependent and -inde-
pendent cell death in urothelial cancer cell lines, indicating that
reduction in miR-145 expression may provide bladder cancer cells
with a selective advantage by inhibition of cell death otherwise
triggered in malignant cells [27]. In our study, the annexin-V apop-
tosis assay showed a signiﬁcant increase in the number of apopto-
tic cells in miR-145-transfected cells compared with the control.
The IGF-IR and the insulin receptor (IR) evolved from a single
ancestral receptor involved in the regulation of metabolism, organ-
ismalsize and longevity. The IGF-IR is a heterotetramer composed
of two a and two b units which possesses tyrosine kinase activity
[28]. Although the two receptors retain a highly conserved struc-
ture, they have acquired distinct functions. The IGF-IR is activated
by its ligands IGF-I and IGF-II, which are produced by the liver and
also by many extrahepatic sites including tumor cells and stromal
ﬁbroblasts. The IR is activated by insulin, which is secreted by thepancreas after food intake [28]. Over the past two decades, many
studies have demonstrated the important role of the IGF-IR in
tumorigenesis, metastasis and resistance to existing forms of can-
cer therapy. Thus, the IGF-IR itself is now regarded as a credible
treatment target.
Regarding the expression of IGF-IR, Rochester observed that the
IGF-IR is up-regulated in bladder cancer compared with non-
malignant bladder [13]. Metalli provided the ﬁrst evidence that
IGF-IR could promote motility and invasion of bladder cancer cells
through Akt- and mitogen-activated protein kinase-dependent
activation of paxillin [12]. Moreover, blockage of IGF-IR signaling
might potentially contribute to the treatment of bladder cancer
cells which were insensitive to chemotherapy. These results sup-
port the hypothesis that the IGF-IR might play an essential role
in the establishment of the invasive phenotype in urothelial neo-
plasia. However, to our knowledge, there has been no earlier study
reporting the interaction between IGF-IR expression and particular
microRNAs in bladder cancer.
Regarding the target genes, there are also earlier studies
showing that miR-145 could directly binds to the insulin receptor
substrate-1 [14], c-Myc [29], mucin 1 [30] and fascin homologue 1
[17]. Shi et al. found that the levels of IGF-IR protein were signiﬁ-
cantly lower in miR-145 transfected cells than in untreated or
mock-transfected cells [14]. We also identiﬁed that miR-145 tar-
gets IGF-IR, using the target prediction algorithms. To validate
the target prediction algorithm results, we performed 30UTR
luciferase assay to see whether miR-145 binds to the 30UTR of
the IGF-IR. We found that relative luciferase level for the IGF-IR
was signiﬁcantly lower in miR-145-transfected bladder cancer
cells than in miR-NC-transfected controls. Furthermore, the pro-
tein expression of IGF-IR was also signiﬁcantly downregulated in
miR-45 transfectants, suggesting that IGF-IR are direct targets of
miR-145. Based on these results, we hypothesized that knockdown
of the target gene (IGF-IR) via miR-145 may be a new therapeutic
approach for bladder cancer.
To validate whether miR-145 plays a tumor-suppressive role by
inhibiting IGF-IR expression, we performed knockdown of IGF-IR in
bladder cancer cells using a siRNA technique. The decreased
expression of IGF-IR was conﬁrmed at the mRNA and protein lev-
els. We then performed function analyses (MTT and wound healing
assays) and observed an effect similar to that of miR-145 overex-
pression, namely that IGF-IR siRNA knockdown resulted in inhibi-
tion of bladder cancer cell proliferation and migration abilities.
Taken together, this evidence suggests that miR-145 may exert
its tumor-suppressive effects through IGF-IR downregulation in
bladder cancer cells. The question of how IGF-IR becomes
overexpressed is still open, but one possible mechanism is through
regulation by microRNAs. Loss of miR-145 may promote aberrant
Z. Zhu et al. / FEBS Letters 588 (2014) 3180–3185 3185expression of IGF-IR contributing to pathogenesis and progression
of bladder cancer.
In summary, our study demonstrates that miR-145 may func-
tion as a tumour suppressor through repression of oncogenic
IGF-IR in bladder cancer. MiR-145 transfection and IGF-IR knock-
down inhibited cell growth, cell migration, and induced apoptosis
in bladder cancer cells. Thus, we postulate that anticancer drugs
containing miR-145 may be used as a novel therapeutic modality.
Further work is needed to assess the applicability of miR-145 in the
treatment of human bladder cancer.
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